Noninvasive vaccination against infectious diseases

References

• Organization WH. World health statistics 2015. Geneva (Switzerland): World Health Organization; 2015. Available online at: http://www.who.int/gho/publications/world_health_statistics/2015/en/
   Google Scholar
• Plotkin SA. Vaccines: the fourth century. Clin Vaccine Immunol. 2009;16:1709–19. doi:10.1128/CVI.00290-09. PMID:19793898
   PubMed Web of Science ®Google Scholar
• Vela Ramirez JE, Sharpe LA, Peppas NA. Current state and challenges in developing oral vaccines. Adv Drug Deliv Rev. 2017;114:116–31. doi:10.1016/j.addr.2017.04.008. PMID:28438674
   PubMed Web of Science ®Google Scholar
• Concha C, Cañas R, Macuer J, Torres MJ, Herrada AA, Jamett F, Ibáñez C. Disease prevention: An opportunity to expand edible plant-based vaccines? Vaccines. 2017;5:14. doi:10.3390/vaccines5020014.
   Web of Science ®Google Scholar
• Irvine DJ, Swartz MA, Szeto GL. Engineering synthetic vaccines using cues from natural immunity. Nat Materials. 2013;12:978–90. doi:10.1038/nmat3775. PMID:24150416
   PubMed Web of Science ®Google Scholar
• Kim SH, Lee KY, Jang YS. Mucosal immune system and M Cell-targeting strategies for oral mucosal vaccination. Immune Network. 2012;12:165–75. doi:10.4110/in.2012.12.5.165. PMID:23213309
   PubMedGoogle Scholar
• Das P. Revolutionary vaccine technology breaks the cold chain. Lancet Infect Dis. 2004;4:719. doi:10.1016/S1473-3099(04)01222-8. PMID:15593445
   PubMed Web of Science ®Google Scholar
• Billah MM, Zaman K, Estivariz CF, Snider CJ, Anand A, Hampton LM, Bari TIA, Russell KL, Chai SJ. Cold-chain adaptability during introduction of inactivated polio vaccine in Bangladesh, 2015. J Infect Dis. 2017;216:S114–S21. doi:10.1093/infdis/jiw591. PMID:28838173
   PubMed Web of Science ®Google Scholar
• Giudice EL, Campbell JD. Needle-free vaccine delivery. Adv Drug Deliv Rev. 2006;58:68–89. doi:10.1016/j.addr.2005.12.003. PMID:16564111
   PubMed Web of Science ®Google Scholar
• Hamilton JG. Needle phobia: a neglected diagnosis. J Fam Pract. 1995;41:169–75. PMID:7636457
   PubMed Web of Science ®Google Scholar
• Nir Y, Paz A, Sabo E, Potasman I. Fear of injections in young adults: Prevalence and associations. Am J Trop Med Hyg. 2003;68:341–4. PMID:12685642
   PubMed Web of Science ®Google Scholar
• Drucker E, Alcabes PG, Marx PA. The injection century: massive unsterile injections and the emergence of human pathogens. Lancet. 2001;358:1989–92. doi:10.1016/S0140-6736(01)06967-7. PMID:11747942
   PubMed Web of Science ®Google Scholar
• Kermode M. Unsafe injections in low-income country health settings: need for injection safety promotion to prevent the spread of blood-borne viruses. Health Promotion Int. 2004;19:95–103. doi:10.1093/heapro/dah110. PMID:14976177
   PubMed Web of Science ®Google Scholar
• Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol. 2012;12:592. doi:10.1038/nri3251. PMID:22828912
   PubMed Web of Science ®Google Scholar
• Fu YH, He JS, Wang XB, Zheng XX, Wu Q, Xie C, Zhang M, Wei W, Tang Q, Song JD, et al. A prime-boost vaccination strategy using attenuated Salmonella typhimurium and a replication-deficient recombinant adenovirus vector elicits protective immunity against human respiratory syncytial virus. Biochem Biophys Res Communications. 2010;395:87–92. doi:10.1016/j.bbrc.2010.03.144. PMID:20350532
   PubMed Web of Science ®Google Scholar
• Klavinskis LS, Barnfield C, Gao L, Parker S. Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts. J Immunol. 1999;162:254–62.
   PubMed Web of Science ®Google Scholar
• Liu L, Yao W, Rao Y, Lu X, Gao J. pH-Responsive carriers for oral drug delivery: challenges and opportunities of current platforms. Drug Deliv. 2017;24:569–81. doi:10.1080/10717544.2017.1279238. PMID:28195032
   PubMed Web of Science ®Google Scholar
• Seong KY, Seo MS, Hwang DY, O'Cearbhaill ED, Sreenan S, Karp JM, Yang SY. A self-adherent, bullet-shaped microneedle patch for controlled transdermal delivery of insulin. J Control Release. 2017;265:48–56. doi:10.1016/j.jconrel.2017.03.041. PMID:28344013
   PubMed Web of Science ®Google Scholar
• Kearney MC, Caffarel-Salvador E, Fallows SJ, McCarthy HO, Donnelly RF. Microneedle-mediated delivery of donepezil: Potential for improved treatment options in Alzheimer's disease. Eur J Pharm Biopharm. 2016;103:43–50. doi:10.1016/j.ejpb.2016.03.026. PMID:27018330
   PubMed Web of Science ®Google Scholar
• Hirobe S, Otsuka R, Iioka H, Quan YS, Kamiyama F, Asada H, Okada N, Nakagawa S. Clinical study of a retinoic acid-loaded microneedle patch for seborrheic keratosis or senile lentigo. Life Sci. 2017;168:24–7. doi:10.1016/j.lfs.2015.12.051. PMID:26757104
   PubMed Web of Science ®Google Scholar
• Hao Y, Dong ML, Zhang TY, Peng JR, Jia YP, Cao YP, Qian Z. Novel approach of using near-Infrared Responsive PEGylated Gold Nanorod Coated Poly(L-lactide) microneedles to enhance the antitumor efficiency of Docetaxel-Loaded MPEG-PDLLA Micelles for Treating an A431 tumor. Acs Appl Mater Inter. 2017;9:15317–27. doi:10.1021/acsami.7b03604.
   PubMed Web of Science ®Google Scholar
• Dietrich G, Griot-Wenk M, Metcalfe IC, Lang AB, Viret J-F. Experience with registered mucosal vaccines. Vaccine. 2003;21:678–83.
   PubMed Web of Science ®Google Scholar
• Wang S, Liu H, Zhang X, Qian F. Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies. Protein Cell. 2015;6:480–503. doi:10.1007/s13238-015-0164-2.
   PubMed Web of Science ®Google Scholar
• Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med. 2005;11:S45–53. doi:10.1038/nm1213. PMID:15812489
   PubMed Web of Science ®Google Scholar
• Strugnell RA, Wijburg OL. The role of secretory antibodies in infection immunity. Nat Rev Microbiol. 2010;8:656–67. doi:10.1038/nrmicro2384. PMID:20694027
   PubMed Web of Science ®Google Scholar
• Rojas R, Apodaca G. Immunoglobulin transport across polarized epithelial cells. Nat Rev Mol Cell Biol. 2002;3:944–55. doi:10.1038/nrm972. PMID:12461560
   PubMed Web of Science ®Google Scholar
• Shakya AK, Chowdhury MYE, Tao W, Gill HS. Mucosal vaccine delivery: Current state and a pediatric perspective. J Control Release. 2016;240:394–413. doi:10.1016/j.jconrel.2016.02.014. PMID:26860287
   PubMed Web of Science ®Google Scholar
• Spencer J, Finn T, Pulford K, Mason D, Isaacson P. The human gut contains a novel population of B lymphocytes which resemble marginal zone cells. Clin Exp Immunol. 1985;62:607. PMID:3910320
   PubMed Web of Science ®Google Scholar
• Spencer J, Sollid L. The human intestinal B-cell response. Mucosal Immunol. 2016. doi:10.1038/mi.2016.59. PMID:27461177
   PubMed Web of Science ®Google Scholar
• Hornquist CE, Ekman L, Grdic KD, Schon K, Lycke NY. Paradoxical IgA immunity in CD4-deficient mice. Lack of cholera toxin-specific protective immunity despite normal gut mucosal IgA differentiation. J Immunol 1995;155:2877–87. PMID:7673704
   PubMed Web of Science ®Google Scholar
• Fischer M, Küppers R. Human IgA‐and IgM‐secreting intestinal plasma cells carry heavily mutated VH region genes. Eur J Immunol. 1998;28:2971–7. doi:10.1002/(SICI)1521-4141(199809)28:09%3c2971::AID-IMMU2971%3e3.0.CO;2-3. PMID:9754584
   PubMed Web of Science ®Google Scholar
• Lindner C, Thomsen I, Wahl B, Ugur M, Sethi MK, Friedrichsen M, et al. Diversification of memory B cells drives the continuous adaptation of secretory antibodies to gut microbiota. Nat Immunol. 2015;16:880–8. doi:10.1038/ni.3213. PMID:26147688
   PubMed Web of Science ®Google Scholar
• Bernstein JM, Baekkevold ES, Brandtzaeg P. Immunobiology of the Tonsils and Adenoids-Chapter 90.
   Google Scholar
• Kunkel EJ, Butcher EC. Plasma-cell homing. Nat Rev Immunol. 2003;3:822–9. doi:10.1038/nri1203. PMID:14523388
   PubMed Web of Science ®Google Scholar
• Hunter MC, Teijeira A, Halin C. T cell trafficking through lymphatic vessels. Frontiers Immunol. 2016;7:613. doi:10.3389/fimmu.2016.00613.
   PubMed Web of Science ®Google Scholar
• Staats HF, Jackson RJ, Marinaro M, Takahashi I, Kiyono H, McGhee JR. Mucosal immunity to infection with implications for vaccine development. Curr Opin Immunol. 1994;6:572–83. doi:10.1016/0952-7915(94)90144-9. PMID:7946045
   PubMed Web of Science ®Google Scholar
• Marasini N, Skwarczynski M, Toth I. Oral delivery of nanoparticle-based vaccines. Exp Rev Vaccin. 2014;13:1361–76. doi:10.1586/14760584.2014.936852. PMID:25155636
   PubMed Web of Science ®Google Scholar
• Pavot V, Rochereau N, Genin C, Verrier B, Paul S. New insights in mucosal vaccine development. Vaccine. 2012;30:142–54. doi:10.1016/j.vaccine.2011.11.003. PMID:22085556
   PubMed Web of Science ®Google Scholar
• Schulz O, Pabst O. Antigen sampling in the small intestine. Trends Immunol. 2013;34:155–61. doi:10.1016/j.it.2012.09.006. PMID:23083727
   PubMed Web of Science ®Google Scholar
• Lee EY, Kim JY, Lee DK, Yoon IS, Ko HL, Chung JW, Chang J, Nam JH. Sublingual immunization with Japanese encephalitis virus vaccine effectively induces immunity through both cellular and humoral immune responses in mice. Microbiol Immunol. 2016;60:846–53. doi:10.1111/1348-0421.12458. PMID:28004418
   PubMed Web of Science ®Google Scholar
• Kamble NM, Hajam IA, Lee JH. Orally administered live attenuated Salmonella Typhimurium protects Q CrossMark mice against lethal infection with H1N1 influenza virus. Vet Microbiol. 2017;201:1–6. doi:10.1016/j.vetmic.2017.01.006. PMID:28284594
   PubMed Web of Science ®Google Scholar
• Wang L, Wang XH, Bi K, Sun XM, Yang J, Gu Y, et al. Oral vaccination with Attenuated Salmonella typhimurium-Delivered TsPmy DNA vaccine Elicits protective immunity against Trichinella spiralis in BALB/c Mice. Plos Neglect Trop D. 2016;10(9): e0004952. doi:10.1371/journal.pntd.0004952.
   Web of Science ®Google Scholar
• Lubeck MD, Davis AR, Chengalvala M, Natuk RJ, Morin JE, Molnar-Kimber K, Mason BB, Bhat BM, Mizutani S, Hung PP, et al. Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc Natl Acad Sci U S A. 1989;86:6763–7. doi:10.1073/pnas.86.17.6763. PMID:2570422
   PubMed Web of Science ®Google Scholar
• Charlton KM, Artois M, Prevec L, Campbell JB, Casey GA, Wandeler AI, Armstrong J. Oral rabies vaccination of skunks and foxes with a recombinant human adenovirus vaccine. Arch Virol. 1992;123:169–79. doi:10.1007/BF01317147. PMID:1550495
   PubMed Web of Science ®Google Scholar
• Fooks AR, Jeevarajah D, Lee J, Warnes A, Niewiesk S, ter Meulen V, Stephenson JR, Clegg JC. Oral or parenteral administration of replication-deficient adenoviruses expressing the measles virus haemagglutinin and fusion proteins: protective immune responses in rodents. J General Virol. 1998;79 (Pt 5):1027–31. doi:10.1099/0022-1317-79-5-1027. PMID:9603317
   PubMed Web of Science ®Google Scholar
• Natuk RJ, Lubeck MD, Chanda PK, Chengalvala M, Wade MS, Murthy SC, Wilhelm J, Vernon SK, Dheer SK, Mizutani S, et al. Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees. AIDS Res Hum Retroviruses. 1993;9:395–404. doi:10.1089/aid.1993.9.395. PMID:8318268
   PubMed Web of Science ®Google Scholar
• Patel A, Zhang Y, Croyle M, Tran K, Gray M, Strong J, Feldmann H, Wilson JM, Kobinger GP. Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice. J Infect Dis. 2007;196 Suppl 2:S413–20. doi:10.1086/520603. PMID:17940978
   PubMed Web of Science ®Google Scholar
• Chen S, Xu Q, Zeng M. Oral vaccination with an adenovirus-vectored vaccine protects against botulism. Vaccine. 2013;31:1009–11. doi:10.1016/j.vaccine.2012.12.054. PMID:23295065
   PubMed Web of Science ®Google Scholar
• Gurwith M, Lock M, Taylor EM, Ishioka G, Alexander J, Mayall T, Ervin JE, Greenberg RN, Strout C, Treanor JJ, et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis. 2013;13:238–50. doi:10.1016/S1473-3099(12)70345-6.
   PubMed Web of Science ®Google Scholar
• Lin J, Tu C, Mou C, Chen X, Yang Q. CpG DNA facilitate the inactivated transmissible gastroenteritis virus in enhancing the local and systemic immune response of pigs via oral administration. Veterinary Immunol Immunopathol. 2016;172:1–8. doi:10.1016/j.vetimm.2016.02.013.
   PubMed Web of Science ®Google Scholar
• Edwards M, Dimmock N. Two influenza A virus-specific Fabs neutralize by inhibiting virus attachment to target cells, while neutralization by their IgGs is complex and occurs simultaneously through fusion inhibition and attachment inhibition. Virology. 2000;278:423–35. doi:10.1006/viro.2000.0631. PMID:11118365
   PubMed Web of Science ®Google Scholar
• Li W, Shi W, Qiao H, Ho SY, Luo A, Zhang Y, Zhu C. Positive selection on hemagglutinin and neuraminidase genes of H1N1 influenza viruses. Virol J. 2011;8:183. doi:10.1186/1743-422X-8-183. PMID:21507270
   PubMed Web of Science ®Google Scholar
• Brandtzaeg P. Mucosal immunity: induction, dissemination, and effector functions. Scandinavian J immunol. 2009;70:505–15. doi:10.1111/j.1365-3083.2009.02319.x. PMID:19906191
   PubMed Web of Science ®Google Scholar
• Shim B-S, Choi Y, Cheon IS, Song MK. Sublingual delivery of vaccines for the induction of mucosal immunity. Immune Network 2013;13:81–5. doi:10.4110/in.2013.13.3.81. PMID:23885221
   PubMedGoogle Scholar
• Spinner JL, Oberoi HS, Yorgensen YM, Poirier DS, Burkhart DJ, Plante M, Evans JT. Methylglycol chitosan and a synthetic TLR4 agonist enhance immune responses to influenza vaccine administered sublingually. Vaccine. 2015;33:5845–53. doi:10.1016/j.vaccine.2015.08.086. PMID:26392012
   PubMed Web of Science ®Google Scholar
• Conner ME, Crawford SE, Barone C, O'Neal C, Zhou YJ, Fernandez F, Parwani A, Saif LJ, Cohen J, Estes MK. Rotavirus subunit vaccines. Arch Virol Suppl. 1996;12:199–206. PMID:9015116
   PubMedGoogle Scholar
• Zhou ZW, Dong H, Huang YM, Yao SW, Liang BS, Xie YQ, Long Y, Mai J, Gong S. Recombinant Bacillus subtilis spores expressing cholera toxin B subunit and Helicobacter pylori urease B confer protection against H. pylori in mice. J Med Microbiol. 2017;66:83–9. doi:10.1099/jmm.0.000404. PMID:27930268
   PubMed Web of Science ®Google Scholar
• Borde A, Ekman A, Larsson A, Carlin N, Holmgren J, Tobias J. Preparation and preclinical evaluation of a freeze-dried formulation of a novel combined multivalent whole-cell/B-subunit oral vaccine against enterotoxigenic Escherichia coli diarrhea. Eur J Pharmaceutics Biopharmaceutics 2016;108:18–24. doi:10.1016/j.ejpb.2016.07.011. PMID:27485398
   PubMed Web of Science ®Google Scholar
• Yagnik B, Sharma D, Padh H, Desai P. Immunization with r-Lactococcus lactis expressing outer membrane protein A of Shigella dysenteriae type-1: evaluation of oral and intranasal route of administration. J Applied Microbiol. 2017;122:493–505. doi:10.1111/jam.13353. PMID:27860045
   PubMed Web of Science ®Google Scholar
• Oliveira CR, Rezende CMF, Silva MR, Borges OM, Pego AP, Goes AM. Oral vaccination based on DNA-Chitosan Nanoparticles against Schistosoma mansoni infection. Sci World J. 2012;2012:938457. doi:10.1100/2012/938457.
   Web of Science ®Google Scholar
• Jazayeri SD, Ideris A, Zakaria Z, Shameli K, Moeini H, Omar AR. Cytotoxicity and immunological responses following oral vaccination of nanoencapsulated avian influenza virus H5 DNA vaccine with green synthesis silver nanoparticles. J Controlled Release. 2012;161:116–23. doi:10.1016/j.jconrel.2012.04.015. PMID:22549012
   PubMed Web of Science ®Google Scholar
• Baldauf KJ, Royal JM, Kouokam JC, Haribabu B, Jala VR, Yaddanapudi K, Hamorsky KT, Dryden GW, Matoba N. Oral administration of a recombinant cholera toxin B subunit promotes mucosal healing in the colon. Mucosal Immunol. 2017;10:887–900. doi:10.1038/mi.2016.95. PMID:27805617
   PubMed Web of Science ®Google Scholar
• Tarakanovskaya MG, Chinburen J, Batchuluun P, Munkhzaya C, Purevsuren G, Dandii D, Hulan T, Oyungerel D, Kutsyna GA, Reid AA, et al. Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L. J Hepatocell Carcino. 2017;4:59–69. doi:10.2147/JHC.S122507.
   PubMed Web of Science ®Google Scholar
• Azegami T, Itoh H, Kiyono H, Yuki Y. Novel transgenic rice-based vaccines. Archivum Immunologiae Et Therapiae Experimentalis 2015;63:87–99. doi:10.1007/s00005-014-0303-0. PMID:25027548
   PubMed Web of Science ®Google Scholar
• Fukuda K, Ishida W, Harada Y, Wakasa Y, Takagi H, Takaiwa F, et al. Efficacy of oral immunotherapy with a rice-based edible vaccine containing hypoallergenic Japanese cedar pollen allergens for treatment of established allergic conjunctivitis in mice. Allergol Int. 2018;67(1):119–23. doi: 10.1016/j.alit.2017.06.006. PMID: 28676431.
   Web of Science ®Google Scholar
• Ogawa T, Kashima K, Yuki Y, Mejima M, Kurokawa S, Kuroda M, Okazawa A, Kiyono H, Ohta D. Seed metabolome analysis of a transgenic rice line expressing cholera Toxin B-subunit. Scientific Reports. 2017;7:5196. doi:10.1038/s41598-017-04701-w. PMID:28701756
   PubMed Web of Science ®Google Scholar
• Takeyama N, Yuki Y, Tokuhara D, Oroku K, Mejima M, Kurokawa S, Kuroda M, Kodama T, Nagai S, Ueda S, et al. Oral rice-based vaccine induces passive and active immunity against enterotoxigenic E. coli-mediated diarrhea in pigs. Vaccine. 2015;33:5204–11. doi:10.1016/j.vaccine.2015.07.074. PMID:26254309
   PubMed Web of Science ®Google Scholar
• Changotra H, Vij A. Rotavirus virus‐like particles (RV‐VLPs) vaccines: An update. Rev Medical Virol. 2017;27(6):e1954. doi:10.1002/rmv.1954. PMID:29048711
   PubMed Web of Science ®Google Scholar
• Dang DA, Nguyen VT, Vu DT, Nguyen TH, Nguyen DM, Yuhuan W, Baoming J, Nguyen DH, Le TL. A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children. Vaccine. 2012;30 Suppl 1:A114–21. PMID:22520120
   PubMed Web of Science ®Google Scholar
• Chen WH, Garza J, Choquette M, Hawkins J, Hoeper A, Bernstein DI, Cohen MB. Safety and immunogenicity of escalating dosages of a single oral administration of peru-15 pCTB, a candidate live, attenuated vaccine against enterotoxigenic Escherichia coli and Vibrio cholerae. Clin Vaccine Immunol. 2015;22:129–35. doi:10.1128/CVI.00560-14. PMID:25410205
   PubMed Web of Science ®Google Scholar
• Liebowitz D, Lindbloom JD, Brandl JR, Garg SJ, Tucker SN. High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial. Lancet Infect Dis. 2015;15:1041–8. doi:10.1016/S1473-3099(15)00266-2. PMID:26333337
   PubMed Web of Science ®Google Scholar
• Baik YO, Choi SK, Kim JW, Yang JS, Kim IY, Kim CW, Hong JH. Safety and immunogenicity assessment of an oral cholera vaccine through phase I clinical trial in Korea. J Korean Medical Sci. 2014;29:494–501. doi:10.3346/jkms.2014.29.4.494. PMID:24753695
   PubMed Web of Science ®Google Scholar
• Zeng M, Mao XH, Li JX, Tong WD, Wang B, Zhang YJ, Guo G, Zhao ZJ, Li L, Wu DL, et al. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;386:1457–64. doi:10.1016/S0140-6736(15)60310-5. PMID:26142048
   PubMed Web of Science ®Google Scholar
• Peters W, Brandl JR, Lindbloom JD, Martinez CJ, Scallan CD, Trager GR, Tingley DW, Kabongo ML, Tucker SN. Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-gamma T cell responses in humans. Vaccine. 2013;31:1752–8. doi:10.1016/j.vaccine.2013.01.023. PMID:23357198
   PubMed Web of Science ®Google Scholar
• Hamborsky J, Kroger A, Wolfe S, Control CfD, Prevention. Epidemiology and prevention of vaccine-preventable diseases. US Dep Health Hum Services, Centers Dis Control Prevention. 2015. Available online at: https://www.cdc.gov/vaccines/pubs/pinkbook/index.html
   Google Scholar
• Hammon WM, Coriell LL, Ludwig EH, McAllister RM, Greene AE, Sather GE, Wehrle PF. Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis: 5. Reanalysis of results based on laboratory-confirmed cases. J Am Medical Assoc. 1954;156:21–7. doi:10.1001/jama.1954.02950010023009. PMID:13183798
   PubMed Web of Science ®Google Scholar
• Koprowski H, Jervis GA, Norton TW. Immune responses in human volunteers upon oral administration of a rodent-adapted strain of poliomyelitis virus. Am J Epidemiol. 1952;55:108–26. doi:10.1093/oxfordjournals.aje.a119499.
   Web of Science ®Google Scholar
• Salk JE, Bazeley P, Bennett BL, Krech U, Lewis LJ, Ward EN, et al. Ii. a practical means for inducing and maintaining antibody formation. Am J Public Health Nations Health. 1954;44:994–1009. doi:10.2105/AJPH.44.8.994.
   PubMed Web of Science ®Google Scholar
• Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005;59:587–635. doi:10.1146/annurev.micro.58.030603.123625. PMID:16153180
   PubMed Web of Science ®Google Scholar
• Sabin AB. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. The University of Chicago Press. J Infect Dis. 1985;151(3):420–36. doi:10.1093/infdis/151.3.420. PMID:2982959
   PubMed Web of Science ®Google Scholar
• Platt LR, Estívariz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis. 2014;210:S380–S9. doi:10.1093/infdis/jiu184. PMID:25316859
   PubMed Web of Science ®Google Scholar
• WHO. Poliomyelitis (Polio), accessed on February 21, 2018. http://www.who.int/ith/vaccines/polio/en/
   Google Scholar
• Top FH, Jr. Control of adenovirus acute respiratory disease in U.S. Army trainees. Yale J Biol Med. 1975;48:185–95. PMID:1099823
   PubMed Web of Science ®Google Scholar
• Kuschner RA, Russell KL, Abuja M, Bauer KM, Faix DJ, Hait H, Henrick J, Jacobs M, Liss A, Lynch JA, et al. A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. military recruits. Vaccine. 2013;31:2963–71. doi:10.1016/j.vaccine.2013.04.035. PMID:23623865
   PubMed Web of Science ®Google Scholar
• Mosley JF, 2nd, Smith LL, Brantley P, Locke D, Como M. Vaxchora: The First FDA-Approved Cholera Vaccination in the United States. P & T. 2017;42:638–40.
   PubMedGoogle Scholar
• Buyse H, Vinals C, Karkada N, Han HH. The human rotavirus vaccine Rotarix in infants: an integrated analysis of safety and reactogenicity. Hum Vaccin Immunother. 2014;10:19–24. doi:10.4161/hv.26476.
   PubMed Web of Science ®Google Scholar
• Justino MC, Araujo EC, van Doorn LJ, Oliveira CS, Gabbay YB, Mascarenhas JD, Miranda YS, Guerra Sde F, Silva VB, Linhares AC. Oral live attenuated human rotavirus vaccine (Rotarix) offers sustained high protection against severe G9P[8]rotavirus gastroenteritis during the first two years of life in Brazilian children. Mem Inst Oswaldo Cruz. 2012;107:846–53. doi:10.1590/S0074-02762012000700002. PMID:23147138
   PubMed Web of Science ®Google Scholar
• Armah GE, Breiman RF, Tapia MD, Dallas MJ, Neuzil KM, Binka FN, Sow SO, Ojwando J, Ciarlet M, Steele AD. Immunogenicity of the pentavalent rotavirus vaccine in African infants. Vaccine. 2012;30 Suppl 1:A86–93. doi:10.1016/j.vaccine.2011.10.006. PMID:22520142
   PubMed Web of Science ®Google Scholar
• Ward RL, Bernstein DI, Smith VE, Sander DS, Shaw A, Eiden JJ, Heaton P, Offit PA, Clark HF. Rotavirus immunoglobulin a responses stimulated by each of 3 doses of a quadrivalent human/bovine reassortant rotavirus vaccine. J Infect Dis. 2004;189:2290–3. doi:10.1086/421248. PMID:15181577
   PubMed Web of Science ®Google Scholar
• Vesikari T. Rotavirus vaccination: a concise review. Clin Microbiol Infect. 2012;18 Suppl 5:57–63. doi:10.1111/j.1469-0691.2012.03981.x. PMID:22882248
   PubMed Web of Science ®Google Scholar
• de Jong HK, Garcia-Laorden MI, Hoogendijk AJ, Parry CM, Maude RR, Dondorp AM, Faiz MA, van der Poll T, Wiersinga WJ. Expression of intra- and extracellular granzymes in patients with typhoid fever. PLoS Negl Trop Dis. 2017;11:e0005823. doi:10.1371/journal.pntd.0005823. PMID:28749963
   PubMed Web of Science ®Google Scholar
• Nisini R, Biselli R, Matricardi PM, Fattorossi A, D'Amelio R. Clinical and immunological response to typhoid vaccination with parenteral or oral vaccines in two groups of 30 recruits. Vaccine. 1993;11:582–6. doi:10.1016/0264-410X(93)90237-R. PMID:8488716
   PubMed Web of Science ®Google Scholar
• Salerno-Goncalves R, Pasetti MF, Sztein MB. Characterization of CD8(+) effector T cell responses in volunteers immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid vaccine. J Immunol. 2002;169:2196–203. doi:10.4049/jimmunol.169.4.2196. PMID:12165550
   PubMed Web of Science ®Google Scholar
• Lundin BS, Johansson C, Svennerholm AM. Oral immunization with a Salmonella enterica serovar typhi vaccine induces specific circulating mucosa-homing CD4(+) and CD8(+) T cells in humans. Infect Immun. 2002;70:5622–7. doi:10.1128/IAI.70.10.5622-5627.2002. PMID:12228290
   PubMed Web of Science ®Google Scholar
• Saha A, Chowdhury MI, Khanam F, Bhuiyan MS, Chowdhury F, Khan AI, Khan IA, Clemens J, Ali M, Cravioto A, et al. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. Vaccine. 2011;29:8285–92. doi:10.1016/j.vaccine.2011.08.108. PMID:21907255
   PubMed Web of Science ®Google Scholar
• Begue RE, Castellares G, Ruiz R, Hayashi KE, Sanchez JL, Gotuzzo E, Oberst RB, Taylor DN, Svennerholm AM. Community-based assessment of safety and immunogenicity of the whole cell plus recombinant B subunit (WC/rBS) oral cholera vaccine in Peru. Vaccine. 1995;13:691–4. doi:10.1016/0264-410X(94)00056-S. PMID:7668039
   PubMed Web of Science ®Google Scholar
• Sanchez JL, Trofa AF, Taylor DN, Kuschner RA, DeFraites RF, Craig SC, Rao MR, Clemens JD, Svennerholm AM, Sadoff JC, et al. Safety and immunogenicity of the oral, whole cell/recombinant B subunit cholera vaccine in North American volunteers. J Infect Dis. 1993;167:1446–9. doi:10.1093/infdis/167.6.1446. PMID:8501336
   PubMed Web of Science ®Google Scholar
• Sirskyj D, Kumar A, Azizi A. Mechanisms underlying the immune response generated by an oral vibrio cholerae vaccine. Int J Mol Sci. 2016;17(7): E1062. doi:10.3390/ijms17071062. PMID: 27384558
   PubMed Web of Science ®Google Scholar
• Alam MM, Riyadh MA, Fatema K, Rahman MA, Akhtar N, Ahmed T, Chowdhury MI, Chowdhury F, Calderwood SB, Harris JB, et al. Antigen-specific memory B-cell responses in Bangladeshi adults after one- or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera. Clin Vaccine Immunol. 2011;18:844–50. doi:10.1128/CVI.00562-10. PMID:21346055
   PubMed Web of Science ®Google Scholar
• Pires A, Fortuna A, Alves G, Falcao A. Intranasal drug delivery: how, why and what for? J Pharm Pharm Sci. 2009;12:288–311. doi:10.18433/J3NC79.
   PubMed Web of Science ®Google Scholar
• Riese P, Sakthivel P, Trittel S, Guzman CA. Intranasal formulations: promising strategy to deliver vaccines. Exp Opin Drug Delivery. 2014;11:1619–34. doi:10.1517/17425247.2014.931936. PMID:24962722
   PubMed Web of Science ®Google Scholar
• Fan SF, Gao YW, Shinya K, Li CK, Li YB, Shi JZ, Jiang Y, Suo Y, Tong T, Zhong G, et al. Immunogenicity and protective efficacy of a live Attenuated H5N1 vaccine in nonhuman primates. PLoS Pathogens. 2009;5:e1000409. doi:10.1371/journal.ppat.1000409. PMID:19412338
   PubMed Web of Science ®Google Scholar
• Yang PH, Duan YQ, Wang C, Xing L, Gao XA, Tang C, Luo D, Zhao Z, Jia W, Peng D, et al. Immunogenicity and protective efficacy of a live attenuated vaccine against the 2009 pandemic A H1N1 in mice and ferrets. Vaccine. 2011;29:698–705. doi:10.1016/j.vaccine.2010.11.026. PMID:21111782
   PubMed Web of Science ®Google Scholar
• Dwivedi V, Manickam C, Patterson R, Dodson K, Murtaugh M, Torrelles JB, Schlesinger LS, Renukaradhya GJ. Cross-protective immunity to porcine reproductive and respiratory syndrome virus by intranasal delivery of a live virus vaccine with a potent adjuvant. Vaccine. 2011;29:4058–66. doi:10.1016/j.vaccine.2011.03.006. PMID:21419162
   PubMed Web of Science ®Google Scholar
• Li JW, Diaz-Arevalo D, Chen YP, Zeng MT. Intranasal vaccination with an engineered influenza virus expressing the receptor binding subdomain of botulinum neurotoxin provides protective immunity against botulism and influenza. Frontiers Immunol. 2015;6:170. doi:10.3389/fimmu.2015.00170. PMID: 25954272
   Web of Science ®Google Scholar
• Li JW, Arevalo MT, Diaz-Arevalo D, Chen YP, Choi JG, Zeng MT. Generation of a safe and effective live viral vaccine by virus self-attenuation using species-specific artificial microRNA. J Controlled Release. 2015;207:70–6. doi:10.1016/j.jconrel.2015.04.001. PMID:25858415
   PubMed Web of Science ®Google Scholar
• Huang MH, Dai SH, Chong PL. Mucosal delivery of a combination adjuvant comprising emulsified fine particles and LD-indolicidin enhances serological immunity to inactivated influenza virus. Microbes Infect. 2016;18:706–9. doi:10.1016/j.micinf.2016.06.007. PMID:27394146
   PubMed Web of Science ®Google Scholar
• Wong G, Richardson JS, Cutts T, Qiu XG, Kobinger GP. Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals. Antiviral Res. 2015;116:17–9. doi:10.1016/j.antiviral.2015.01.001. PMID:25596432
   PubMed Web of Science ®Google Scholar
• Malley R, Lipsitch M, Stack A, Saladino R, Fleisher G, Pelton S, Thompson C, Briles D, Anderson P. Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci. Infect Immunity. 2001;69:4870–3. doi:10.1128/IAI.69.8.4870-4873.2001. PMID:11447162
   PubMed Web of Science ®Google Scholar
• Okamoto S, Kawabata S, Fujitaka H, Uehira T, Okuno Y, Hamada S. Vaccination with formalin-inactivated influenza vaccine protects mice against lethal influenza Streptococcus pyogenes superinfection. Vaccine. 2004;22:2887–93. doi:10.1016/j.vaccine.2003.12.024. PMID:15246625
   PubMed Web of Science ®Google Scholar
• Kraan H, Soema P, Amorij JP, Kersten G. Intranasal and sublingual delivery of inactivated polio vaccine. Vaccine. 2017;35:2647–53. doi:10.1016/j.vaccine.2017.03.090. PMID:28400164
   PubMed Web of Science ®Google Scholar
• Harakuni T, Kohama H, Tadano M, Uechi G, Tsuji N, Matsumoto Y, Miyata T, Tsuboi T, Oku H, Arakawa T. Mucosal Vaccination Approach against Mosquito-Borne Japanese Encephalitis Virus. Jpn J Infect Dis. 2009;62:37–45. PMID:19168957
   PubMed Web of Science ®Google Scholar
• Arnaboldi PM, Sambir M, D'Arco C, Peters LA, Seegers JFML, Mayer L, McCormick AA, Dattwyler RJ. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague. Vaccine. 2016;34:5768–76. doi:10.1016/j.vaccine.2016.09.063. PMID:27745954
   PubMed Web of Science ®Google Scholar
• Zeng WG, Tan ACL, Horrocks K, Jackson DC. A lipidated form of the extracellular domain of influenza M2 protein as a self-adjuvanting vaccine candidate. Vaccine. 2015;33:3526–32. doi:10.1016/j.vaccine.2015.05.053. PMID:26049002
   PubMed Web of Science ®Google Scholar
• Nochi T, Yuki Y, Takahashi H, Sawada S, Mejima M, Kohda T, Harada N, Kong IG, Sato A, Kataoka N, et al. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat Mater. 2010;9:572–8. doi:10.1038/nmat2784. PMID:20562880
   PubMed Web of Science ®Google Scholar
• Li JW, Arevalo MT, Chen YP, Posadas O, Smith JA, Zeng MT. Intranasal immunization with influenza antigens conjugated with cholera toxin subunit B stimulates broad spectrum immunity against influenza viruses. Hum Vaccin Immunother. 2014;10:1211–20. doi:10.4161/hv.28407.
   PubMed Web of Science ®Google Scholar
• Sakai S, Takashima Y, Matsumoto Y, Reed SG, Hayashi Y, Matsumoto Y. Intranasal immunization with Leish-111f induces IFN-gamma production and protects mice from Leishmania major infection. Vaccine. 2010;28:2207–13. doi:10.1016/j.vaccine.2009.12.055. PMID:20056184
   PubMed Web of Science ®Google Scholar
• Cui YL, Zhang XM, Gong Y, Niu SQ, Yin NL, Yao R, Xu W, Li D, Wang H, He Y, et al. Immunization with DnaJ (hsp40) could elicit protection against nasopharyngeal colonization and invasive infection caused by different strains of Streptococcus pneumoniae. Vaccine. 2011;29:1736–44. doi:10.1016/j.vaccine.2010.12.126. PMID:21238570
   PubMed Web of Science ®Google Scholar
• Medina M, Villena J, Salva S, Vintini E, Langella P, Alvarez S. Nasal administration of Lactococcus lactis improves local and systemic immune responses against Streptococcus pneumoniae. Microbiol Immunol. 2008;52:399–409. doi:10.1111/j.1348-0421.2008.00050.x. PMID:18667039
   PubMed Web of Science ®Google Scholar
• Maunder HE, Taylor G, Leppard KN, Easton AJ. Intranasal immunisation with recombinant adenovirus vaccines protects against a lethal challenge with pneumonia virus of mice. Vaccine. 2015;33:6641–9. doi:10.1016/j.vaccine.2015.10.105. PMID:26529077
   PubMed Web of Science ®Google Scholar
• Rivera-Hernandez T, Hartas J, Wu Y, Chuan YP, Lua LHL, Good M, Batzloff MR, Middelberg AP. Self-adjuvanting modular virus-like particles for mucosal vaccination against group A streptococcus (GAS). Vaccine. 2013;31:1950–5. doi:10.1016/j.vaccine.2013.02.013. PMID:23422147
   PubMed Web of Science ®Google Scholar
• Cai MY, Wang C, Li YF, Gu HJ, Sun SJ, Duan YQ, et al. Virus-like particle vaccine by intranasal vaccination elicits protective immunity against respiratory syncytial viral infection in mice. Acta Bioch Bioph Sin. 2017;49:74–82. doi:10.1093/abbs/gmw118.
   PubMed Web of Science ®Google Scholar
• Poteet E, Lewis P, Chen CY, Ho SO, Do T, Chiang SM, Labranche C, Montefiori D, Fujii G, Yao Q. Toll-like receptor 3 adjuvant in combination with virus-like particles elicit a humoral response against HIV. Vaccine. 2016;34:5886–94. doi:10.1016/j.vaccine.2016.10.036. PMID:27997339
   PubMed Web of Science ®Google Scholar
• Ji XL, Ren ZG, Xu N, Meng LN, Yu ZJ, Feng N, Sang X, Li S, Li Y, Wang T, et al. Intranasal immunization with influenza virus-like particles containing membrane-anchored Cholera Toxin B or Ricin Toxin B enhances adaptive immune responses and protection against an antigenically distinct virus. Viruses-Basel. 2016;8:115. doi:10.3390/v8040115.
   PubMed Web of Science ®Google Scholar
• Hjelm BE, Kilbourne J, Herbst-Kralovetz MM. TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines. Hum Vaccin Immunother. 2014;10:410–6. doi:10.4161/hv.27147.
   PubMed Web of Science ®Google Scholar
• Jackson EM, Herbst-Kralovetz MM. Intranasal Vaccination with Murabutide Enhances Humoral and Mucosal immune responses to a virus-like particle vaccine. Plos One. 2012;7:e41529. doi:10.1371/journal.pone.0041529. PMID: 22855691
   Web of Science ®Google Scholar
• Riquelme-Neira R, Rivera A, Saez D, Fernandez P, Osorio G, del Canto F, et al. Vaccination with DNA Encoding Truncated Enterohemorrhagic Escherichia coli (EHEC) Factor for Adherence-1 Gene (efa-1′) Confers Protective Immunity to Mice Infected with E. coli O157:H7. Front Cell Infect Microbiol. 2015;5:104. PMID:26835434
   PubMed Web of Science ®Google Scholar
• Su LK, Yu F, Li ZF, Zeng C, Xu QA, Fan MW. Intranasal co-delivery of IL-6 gene enhances the immunogenicity of anti-caries DNA vaccine. Acta Pharmacologica Sinica. 2014;35:592–8. doi:10.1038/aps.2013.184. PMID:24705100
   PubMed Web of Science ®Google Scholar
• Rolland-Debord C, Lair D, Roussey-Bihouee T, Hassoun D, Evrard J, Cheminant MA, Chesné J, Braza F, Mahay G, Portero V, et al. Block copolymer/DNA vaccination induces a strong allergen-specific local response in a mouse model of house dust mite asthma. PLoS One. 2014;9:e85976. doi:10.1371/journal.pone.0085976. PMID:24497934
   PubMed Web of Science ®Google Scholar
• Qin T, Yin Y, Huang L, Yu Q, Yang Q. H9N2 influenza whole inactivated virus combined with polyethyleneimine strongly enhances mucosal and systemic immunity after intranasal immunization in mice. Clin Vaccine Immunol. 2015;22:421–9. doi:10.1128/CVI.00778-14. PMID:25673304
   PubMed Web of Science ®Google Scholar
• Zhao K, Rong G, Hao Y, Yu L, Kang H, Wang X, Wang X, Jin Z, Ren Z, Li Z. IgA response and protection following nasal vaccination of chickens with Newcastle disease virus DNA vaccine nanoencapsulated with Ag@SiO2 hollow nanoparticles. Sci Rep. 2016;6:25720. doi:10.1038/srep25720. PMID:27170532
   PubMed Web of Science ®Google Scholar
• Li M, Zhao MN, Fu Y, Li Y, Gong T, Zhang ZR, Sun X. Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra- and paracellular pathways. J Controlled Release. 2016;228:9–19. doi:10.1016/j.jconrel.2016.02.043. PMID:26941035
   PubMed Web of Science ®Google Scholar
• Gomez M, Mufson MA, Dubovsky F, Knightly C, Zeng W, Losonsky G. Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children. Pediatric Infect Dis J. 2009;28:655–8. doi:10.1097/INF.0b013e318199c3b1. PMID:19483659
   PubMed Web of Science ®Google Scholar
• Malkin E, Yogev R, Abughali N, Sliman J, Wang CK, Zuo F, Yang CF, Eickhoff M, Esser MT, Tang RS, et al. Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age. PLoS One. 2013;8:e77104. doi:10.1371/journal.pone.0077104. PMID:24204744
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Malkin E, Abughali N, Falloon J, Yi T, Dubovsky F, MI-CP149 Investigators. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatric Infect Dis J. 2012;31:109–14. doi:10.1097/INF.0b013e31823386f1.
   PubMed Web of Science ®Google Scholar
• Yang CF, Wang CK, Malkin E, Schickli JH, Shambaugh C, Zuo F, Galinski MS, Dubovsky F, Study Group, Tang RS. Implication of respiratory syncytial virus (RSV) F transgene sequence heterogeneity observed in Phase 1 evaluation of MEDI-534, a live attenuated parainfluenza type 3 vectored RSV vaccine. Vaccine. 2013;31:2822–7. doi:10.1016/j.vaccine.2013.04.006. PMID:23602668
   PubMed Web of Science ®Google Scholar
• Thorstensson R, Trollfors B, Al-Tawil N, Jahnmatz M, Bergstrom J, Ljungman M, Bergström J, Ljungman M, Törner A, Wehlin L, et al. A phase I clinical study of a live attenuated Bordetella pertussis vaccine–BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers. PLoS One. 2014;9:e83449. doi:10.1371/journal.pone.0083449. PMID:24421886
   PubMed Web of Science ®Google Scholar
• Jahnmatz M, Amu S, Ljungman M, Wehlin L, Chiodi F, Mielcarek N, Locht C, Thorstensson R. B-cell responses after intranasal vaccination with the novel attenuated Bordetella pertussis vaccine strain BPZE1 in a randomized phase I clinical trial. Vaccine. 2014;32:3350–6. doi:10.1016/j.vaccine.2014.04.048. PMID:24793938
   PubMed Web of Science ®Google Scholar
• Schnoeller C, Roux X, Sawant D, Raze D, Olszewska W, Locht C, Openshaw PJ. Attenuated Bordetella pertussis vaccine protects against respiratory syncytial virus disease via an IL-17-dependent mechanism. Am J Respir Critical Care Med. 2014;189:194–202.
   PubMed Web of Science ®Google Scholar
• Brekke K, Lind A, Holm-Hansen C, Haugen IL, Sorensen B, Sommerfelt M, Kvale D. Intranasal administration of a therapeutic HIV vaccine (Vacc-4x) induces dose-dependent systemic and mucosal immune responses in a randomized controlled trial. PLoS One. 2014;9:e112556. doi:10.1371/journal.pone.0112556. PMID:25398137
   PubMed Web of Science ®Google Scholar
• Atmar RL, Bernstein DI, Harro CD, Al-Ibrahim MS, Chen WH, Ferreira J, Estes MK, Graham DY, Opekun AR, Richardson C, et al. Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med. 2011;365:2178–87. doi:10.1056/NEJMoa1101245. PMID:22150036
   PubMed Web of Science ®Google Scholar
• El-Kamary SS, Pasetti MF, Mendelman PM, Frey SE, Bernstein DI, Treanor JJ, Ferreira J, Chen WH, Sublett R, Richardson C, et al. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J Infect Dis. 2010;202:1649–58. doi:10.1086/657087. PMID:20979455
   PubMed Web of Science ®Google Scholar
• Lambkin-Williams R, Gelder C, Broughton R, Mallett CP, Gilbert AS, Mann A, He D, Oxford JS, Burt D. An intranasal proteosome-adjuvanted trivalent influenza vaccine is safe, immunogenic & efficacious in the human viral influenza challenge model. Serum IgG & Mucosal IgA are important correlates of protection against illness associated with infection. PLoS One. 2016;11:e0163089. doi:10.1371/journal.pone.0163089. PMID:28005959
   PubMed Web of Science ®Google Scholar
• Mallory RM, Malkin E, Ambrose CS, Bellamy T, Shi L, Yi T, Jones T, Kemble G, Dubovsky F. Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials. PLoS One. 2010;5:e13755. doi:10.1371/journal.pone.0013755. PMID:21060780
   PubMed Web of Science ®Google Scholar
• Traynor K. First quadrivalent flu vaccine approved. Am J Health-Syst Pharm. 2012;69:538.
   Web of Science ®Google Scholar
• Block SL, Yi T, Sheldon E, Dubovsky F, Falloon J. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults. Vaccine. 2011;29:9391–7. doi:10.1016/j.vaccine.2011.09.109. PMID:21983154
   PubMed Web of Science ®Google Scholar
• Nigwekar PV, Kumar A, Padbidri VV, Choudhury A, Chaudhari AB, Kulkarni PS. Safety of Russian-Backbone Trivalent, Live Attenuated Seasonal Influenza Vaccine in Healthy Subjects: Open-Label, Non-randomized Phase 4 Study. Drug safety. 2017.
   Web of Science ®Google Scholar
• Glück R, Mischler R, Durrer P, Fürer E, Lang AB, Herzog C, et al. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Eschevichia coli Heat-Labile Toxin as a Mucosal Adjuvant. J Infect Dis. 2000;181:1129–32. doi:10.1086/315337. PMID:10720540
   PubMed Web of Science ®Google Scholar
• Glück U, Gebbers J-O, Glück R. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J Virol. 1999;73:7780–6. PMID:10438868
   PubMed Web of Science ®Google Scholar
• Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, Spyr C, Steffen R. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Eng J Med. 2004;350:896–903. doi:10.1056/NEJMoa030595. PMID:14985487
   PubMed Web of Science ®Google Scholar
• Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Exp Rev Vaccines. 2008;7:1201–14. doi:10.1586/14760584.7.8.1201. PMID:18844594
   PubMed Web of Science ®Google Scholar
• Henri S, Guilliams M, Poulin LF, Tamoutounour S, Ardouin L, Dalod M, Malissen B. Disentangling the complexity of the skin dendritic cell network. Immunol Cell Biol. 2010;88:366–75. doi:10.1038/icb.2010.34.
   PubMed Web of Science ®Google Scholar
• Doebel T, Voisin B, Nagao K. Langerhans cells–the macrophage in dendritic cell clothing. Trends Immunol. 2017;38(157):817–28. doi:10.1016/j.it.2017.06.008. PMID:28720426
   PubMed Web of Science ®Google Scholar
• Figdor CG, van Kooyk Y, Adema GJ. C-type lectin receptors on dendritic cells and Langerhans cells. Nat Rev Immunol. 2002;2:77–84. doi:10.1038/nri723. PMID:11910898
   PubMed Web of Science ®Google Scholar
• Belyakov IM, Hammond SA, Ahlers JD, Glenn GM, Berzofsky JA. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest 2004;113:998–1007. doi:10.1172/JCI20261. PMID:15057306
   PubMed Web of Science ®Google Scholar
• Pulit-Penaloza JA, Esser ES, Vassilieva EV, Lee JW, Taherbhai MT, Pollack BP, Prausnitz MR, Compans RW, Skountzou I. A protective role of murine langerin(+) cells in immune responses to cutaneous vaccination with microneedle patches. Sci Rep. 2014;4:6094. doi:10.1038/srep06094. PMID:25130187
   PubMed Web of Science ®Google Scholar
• Butler D. Measles by the numbers: A race to eradication. Nature. 2015;518:148–9. doi:10.1038/518148a. PMID:25673392
   PubMed Web of Science ®Google Scholar
• Shah V, Choudhury BK. Fabrication, physicochemical characterization, and performance evaluation of biodegradable polymeric microneedle patch system for enhanced transcutaneous flux of high molecular weight therapeutics. AAPS PharmSciTech. 2017;18(8):2936 01502948. doi:10.1208/s12249-017-0774-5. PMID: 28432615
   Web of Science ®Google Scholar
• Tu J, Du G, Reza Nejadnik M, Monkare J, van der Maaden K, Bomans PHH, Sommerdijk NAJM, Slütter B, Jiskoot W, Bouwstra JA, et al. Mesoporous Silica Nanoparticle-Coated Microneedle arrays for intradermal antigen delivery. Pharm Res. 2017;34(8):1693–706. doi:10.1007/s11095-017-2177-4. PMID:28536970
   PubMed Web of Science ®Google Scholar
• Boks MA, Unger WW, Engels S, Ambrosini M, Kooyk Y, Luttge R. Controlled release of a model vaccine by nanoporous ceramic microneedle arrays. Int J Pharm. 2015;491:375–83. doi:10.1016/j.ijpharm.2015.06.025. PMID:26116016
   PubMed Web of Science ®Google Scholar
• Kim SJ, Shin JH, Noh JY, Song CS, Kim YC. Development of the novel coating formulations for skin vaccination using stainless steel microneedle. Drug Deliv Transl Re. 2016;6:486–97. doi:10.1007/s13346-016-0321-z.
   PubMed Web of Science ®Google Scholar
• Ayittey PN, Walker JS, Rice JJ, de Tombe PP. Glass microneedles for force measurements: a finite-element analysis model. Pflug Arch Eur J Phy. 2009;457:1415–22. doi:10.1007/s00424-008-0605-3.
   PubMed Web of Science ®Google Scholar
• Nguyen HX, Banga AK. Fabrication, characterization and application of sugar microneedles for transdermal drug delivery. Ther Deliv. 2017;8:249–64. doi:10.4155/tde-2016-0096. PMID:28361607
   PubMed Web of Science ®Google Scholar
• Caffarel-Salvador E, Brady AJ, Eltayib E, Meng T, Alonso-Vicente A, Gonzalez-Vazquez P, Torrisi BM, Vicente-Perez EM, Mooney K, Jones DS, et al. Hydrogel-forming microneedle arrays allow detection of drugs and glucose In Vivo: Potential for use in diagnosis and therapeutic drug monitoring. Plos One. 2015;10(10)12:e0145644. doi:10.1371/journal.pone.0145644. PMID: 26717198
   PubMed Web of Science ®Google Scholar
• Hoang MT, Ita KB, Bair DA. Solid microneedles for transdermal delivery of amantadine hydrochloride and pramipexole dihydrochloride. Pharmaceutics. 2015;7:379–96. doi:10.3390/pharmaceutics7040379. PMID:26426039
   PubMed Web of Science ®Google Scholar
• Baek SH, Shin JH, Kim YC. Drug-coated microneedles for rapid and painless local anesthesia. Biomed Microdevices. 2017;19:2. doi:10.1007/s10544-016-0144-1. PMID:28070698
   PubMed Web of Science ®Google Scholar
• Ito Y, Hamasaki N, Higashino H, Murakami Y, Miyamoto N, Takada K. Method to increase the systemically delivered amount of drug from dissolving microneedles. Chem Pharm Bull. 2013;61:8–15. doi:10.1248/cpb.c12-00468.
   PubMed Web of Science ®Google Scholar
• Yu W, Jiang G, Liu D, Li L, Chen H, Liu Y, Huang Q, Tong Z, Yao J, Kong X. Fabrication of biodegradable composite microneedles based on calcium sulfate and gelatin for transdermal delivery of insulin. Mater Sci Eng C Mater Biol Appl. 2017;71:725–34. doi:10.1016/j.msec.2016.10.063.
   PubMed Web of Science ®Google Scholar
• Wiggan O, Livengood JA, Silengo SJ, Kinney RM, Osorio JE, Huang CYH, Stinchcomb DT. Novel formulations enhance the thermal stability of live-attenuated flavivirus vaccines. Vaccine. 2011;29:7456–62. doi:10.1016/j.vaccine.2011.07.054. PMID:21803103
   PubMed Web of Science ®Google Scholar
• Gay NJ. The theory of measles elimination: implications for the design of elimination strategies. J Infect Dis. 2004;189 Suppl 1:S27–35. doi:10.1086/381592. PMID:15106086
   PubMed Web of Science ®Google Scholar
• Edens C, Collins ML, Ayers J, Rota PA, Prausnitz MR. Measles vaccination using a microneedle patch. Vaccine. 2013;31:3403–9. doi:10.1016/j.vaccine.2012.09.062. PMID:23044406
   PubMed Web of Science ®Google Scholar
• Li N, Wang N, Wang XT, Zhen YY, Wang T. Microneedle arrays delivery of the conventional vaccines based on nonvirulent viruses. Drug Delivery. 2016;23:3234–47. doi:10.3109/10717544.2016.1165311. PMID:26967666
   PubMed Web of Science ®Google Scholar
• Edens C, Collins ML, Goodson JL, Rota PA, Prausnitz MR. A microneedle patch containing measles vaccine is immunogenic in non-human primates. Vaccine 2015;33:4712–8. doi:10.1016/j.vaccine.2015.02.074. PMID:25770786
   PubMed Web of Science ®Google Scholar
• Ding Z, Verbaan FJ, Bivas-Benita M, Bungener L, Huckriede A, van den Berg DJ, Kersten G, Bouwstra JA. Microneedle arrays for the transcutaneous immunization of diphtheria and influenza in BALB/c mice. J Controlled Release. 2009;136:71–8. doi:10.1016/j.jconrel.2009.01.025. PMID:19331846
   PubMed Web of Science ®Google Scholar
• Vrdoljak A, McGrath MG, Carey JB, Draper SJ, Hill AVS, O'Mahony C, Crean AM, Moore AC. Coated microneedle arrays for transcutaneous delivery of live virus vaccines. J Controlled Release. 2012;159:34–42. doi:10.1016/j.jconrel.2011.12.026. PMID:22245683
   PubMed Web of Science ®Google Scholar
• Kim E, Erdos G, Huang SH, Kenniston T, Falo LD, Gambotto A. Preventative vaccines for Zika Virus outbreak: Preliminary evaluation. Ebiomedicine. 2016;13:315–20. doi:10.1016/j.ebiom.2016.09.028. PMID:27717627
   PubMed Web of Science ®Google Scholar
• Carey JB, Vrdoljak A, O'Mahony C, Hill AVS, Draper SJ, Moore AC. Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route. Sci Reports. 2014;4;6154. doi:10.1038/srep06154. PMID:25142082
   PubMed Web of Science ®Google Scholar
• Wang YH, Vlasova A, Velasquez DE, Saif LJ, Kandasamy S, Kochba E, Levin Y, Jiang B. Skin Vaccination against Rotavirus Using Microneedles: Proof of Concept in Gnotobiotic Piglets. Plos One. 2016;11:e0166038. doi:10.1371/journal.pone.0166038. PMID:27824918
   PubMed Web of Science ®Google Scholar
• Muller DA, Pearson FE, Fernando GJP, Agyei-Yeboah C, Owens NS, Corrie SR, Crichton ML, Wei JC, Weldon WC, Oberste MS, et al. Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses. Sci Reports. 2016;6:22094. doi:10.1038/srep22094. PMID:26911254
   PubMed Web of Science ®Google Scholar
• Weldon WC, Martin MP, Zarnitsyn V, Wang BZ, Koutsonanos D, Skountzou I, Prausnitz MR, Compans RW. Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity. Clin Vaccine Immunol. 2011;18:647–54. doi:10.1128/CVI.00435-10.
   PubMed Web of Science ®Google Scholar
• Kommareddy S, Baudner BC, Bonificio A, Gallorini S, Palladino G, Determan AS, Dohmeier DM, Kroells KD, Sternjohn JR, Singh M, et al. Influenza subunit vaccine coated microneedle patches elicit comparable immune responses to intramuscular injection in guinea pigs. Vaccine 2013;31:3435–41. doi:10.1016/j.vaccine.2013.01.050. PMID:23398932
   PubMed Web of Science ®Google Scholar
• Mikszta JA, Dekker JP, Harvey NG, Dean CH, Brittingham JM, Huang J, Sullivan VJ, Dyas B, Roy CJ, Ulrich RG. Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine. Infect Immunity. 2006;74:6806–10. doi:10.1128/IAI.01210-06. PMID:17030580
   PubMed Web of Science ®Google Scholar
• Song JM, Kim YC, Lipatov AS, Pearton M, Davis CT, Yoo DG, Park KM, Chen LM, Quan FS, Birchall JC, et al. Microneedle delivery of H5N1 influenza virus-like particles to the skin induces Long-Lasting B- and T-Cell responses in mice. Clin Vaccine Immunol. 2010;17:1381–9. doi:10.1128/CVI.00100-10. PMID:20631330
   PubMed Web of Science ®Google Scholar
• Kim MC, Lee JW, Choi HJ, Lee YN, Hwang HS, Lee J, Kim C, Lee JS, Montemagno C, Prausnitz MR, et al. Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection. J Controlled Release. 2015;210:208–16. doi:10.1016/j.jconrel.2015.05.278. PMID:26003039
   PubMed Web of Science ®Google Scholar
• Hooper JW, Golden JW, Ferro AM, King AD. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine. 2007;25:1814–23. doi:10.1016/j.vaccine.2006.11.017. PMID:17240007
   PubMed Web of Science ®Google Scholar
• Alarcon JB, Hartley AW, Harvey NG, Mikszta JA. Preclinical evaluation of microneedle technology for intradermal delivery of influenza vaccines. Clin Vaccine Immunol. 2007;14:375–81. doi:10.1128/CVI.00387-06. PMID:17329444
   PubMed Web of Science ®Google Scholar
• Song JM, Kim YC, O EJ, Compans RW, Prausnitz MR, Kang SM. DNA vaccination in the skin using microneedles improves protection against influenza. Mol Therapy. 2012;20:1472–80. doi:10.1038/mt.2012.69. PMID:22508490
   PubMed Web of Science ®Google Scholar
• Matsuo K, Hirobe S, Yokota Y, Ayabe Y, Seto M, Quan YS, Kamiyama F, Tougan T, Horii T, Mukai Y, et al. Transcutaneous immunization using a dissolving microneedle array protects against tetanus, diphtheria, malaria, and influenza. J Controlled Release. 2012;160:495–501. doi:10.1016/j.jconrel.2012.04.001. PMID:22516091
   PubMed Web of Science ®Google Scholar
• Perdue ML, Arnold F, Li S, Donabedian A, Cioce V, Warf T, Huebner R. The future of cell culture-based influenza vaccine production. Exp Rev Vaccin. 2011;10:1183–94. doi:10.1586/erv.11.82. PMID:21854311
   PubMed Web of Science ®Google Scholar
• Endmann A, Kluender K, Kapp K, Riede O, Oswald D, Talman EG, Schroff M, Kleuss C, Ruiters MH, Juhls C. Cationic lipid-formulated DNA vaccine against Hepatitis B virus: Immunogenicity of MIDGE-Th1 vectors encoding small and large surface antigen in comparison to a licensed protein vaccine. Plos One. 2014;9(7):e101715. doi:10.1371/journal.pone.0101715. PMID:24992038
   PubMed Web of Science ®Google Scholar
• Cole G, McCaffrey J, Ali AA, McBride JW, McCrudden CM, Vincente-Perez EM, et al. Dissolving microneedles for DNA vaccination: Improving functionality via polymer characterization and RALA complexation. Hum Vaccin Immunother. 2017;13:50–62. doi:10.1080/21645515.2016.1248008.
   PubMed Web of Science ®Google Scholar
• Qiu YQ, Guo L, Zhang SH. DNA-based vaccination against hepatitis B virus using dissolving microneedle arrays adjuvanted by cationic liposomes and CpG ODN (vol 23, pg 2391, 2015). Drug Delivery. 2016;23:3179. PMID:26679752
   PubMed Web of Science ®Google Scholar
• Kim NW, Lee MS, Kim KR, Lee JE, Lee K, Park JS, Matsumoto Y, Jo DG, Lee H, Lee DS, et al. Polyplex-releasing microneedles for enhanced cutaneous delivery of DNA vaccine. J Controlled Release. 2014;179:11–7. doi:10.1016/j.jconrel.2014.01.016. PMID:24462900
   PubMed Web of Science ®Google Scholar
• Yang HW, Ye L, Guo XD, Yang CL, Compans RW, Prausnitz MR. Ebola vaccination using a DNA vaccine coated on PLGA-PLL/gamma PGA nanoparticles administered using a microneedle patch. Adv Healthc Mater. 2017;6(1):1600750. doi:10.1002/adhm.201600750.
   Web of Science ®Google Scholar
• Seok H, Noh JY, Lee DY, Kim SJ, Song CS, Kim YC. Effective humoral immune response from a H1N1 DNA vaccine delivered to the skin by microneedles coated with PLGA-based cationic nanoparticles. J Control Release. 2017;265:66–74. doi:10.1016/j.jconrel.2017.04.027. PMID:28434892
   PubMed Web of Science ®Google Scholar
• Arya JM, Dewitt K, Scott-Garrard M, Chiang YW, Prausnitz MR. Rabies vaccination in dogs using a dissolving microneedle patch. J Controlled Release. 2016;239:19–26. doi:10.1016/j.jconrel.2016.08.012. PMID:27524283
   PubMed Web of Science ®Google Scholar
• Kim YC, Yoo DG, Compans RW, Kang SM, Prausnitz MR. Cross-protection by co-immunization with influenza hemagglutinin DNA and inactivated virus vaccine using coated microneedles. J Controlled Release 2013;172:579–88. doi:10.1016/j.jconrel.2013.04.016. PMID:23643528
   PubMed Web of Science ®Google Scholar
• Rouphael NG, Paine M, Mosley R, Henry S, McAllister DV, Kalluri H, Pewin W, Frew PM, Yu T, Thornburg NJ, et al. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial. Lancet 2017;390:649–58. doi:10.1016/S0140-6736(17)30575-5. PMID:28666680
   PubMed Web of Science ®Google Scholar
• Estivariz CF, Snider CJ, Anand A, Hampton LM, Bari TI, Billah MM, Chai SJ, Wassilak SG, Heffelfinger JD, Zaman K. Lessons learned from the introduction of inactivated Poliovirus vaccine in Bangladesh. J Infect Dis. 2017;216:S122–S9. doi:10.1093/infdis/jiw510. PMID:28838154
   PubMed Web of Science ®Google Scholar
• Mudie DM, Amidon GL, Amidon GE. Physiological parameters for oral delivery and in vitro testing. Mol Pharm 2010;7:1388–405. doi:10.1021/mp100149j. PMID:20822152
   PubMed Web of Science ®Google Scholar
• Posgai AL, Wasserfall CH, Kwon KC, Daniell H, Schatz DA, Atkinson MA. Plant-based vaccines for oral delivery of type 1 diabetes-related autoantigens: Evaluating oral tolerance mechanisms and disease prevention in NOD mice. Sci Rep. 2017;7:42372. doi:10.1038/srep42372. PMID:28205558
   PubMed Web of Science ®Google Scholar
• Price DN, Kusewitt DF, Lino CA, McBride AA, Muttil P. Oral tolerance to environmental Mycobacteria interferes with Intradermal, but not pulmonary, immunization against Tuberculosis. PLoS Pathog. 2016;12:e1005614. doi:10.1371/journal.ppat.1005614. PMID:27153120
   PubMed Web of Science ®Google Scholar
• Wang T, Zhen Y, Ma X, Wei B, Li S, Wang N. Mannosylated and lipid A-incorporating cationic liposomes constituting microneedle arrays as an effective oral mucosal HBV vaccine applicable in the controlled temperature chain. Colloids Surf B Biointerfaces. 2015;126:520–30. doi:10.1016/j.colsurfb.2015.01.005. PMID:25612819
   PubMed Web of Science ®Google Scholar